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in patients with response to therapy resulting in a small-
er area under the curve of days 1–3 (AUC) than in those 
with progressive disease (p = 0.028). The other param-
eters did not indicate the response to therapy at the initial 
treatment phase. In conclusion, the course of nucleo-
somes (AUC) might be valuable for the early prediction 
of therapy response in preoperatively treated colorectal 
cancer patients. 
 Copyright © 2006 S. Karger AG, Basel 
 Introduction 
 Colorectal cancer ranks as the third most common 
cancer in men and women. It is the second leading cause 
of cancer death in the United States  [1] . Besides surgery, 
therapeutic options include radiotherapy, chemotherapy 
and also a combination of both. In these systemic mo-
dalities, apoptosis is one of the main mechanism leading 
to the demise of cancer cells. 
 Nucleosomes, which are complexes formed by an oc-
tamer of histones with DNA twisted around, are typical 
products of apoptotic cell death  [2, 3] . They are the basic 
elements of chromatin that is, during apoptosis, cleaved 
into mono- and oligonucleosomes by endonucleases  [4, 
5] . These particles are packed into apoptotic bodies and 
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 Abstract 
 Apoptotic markers and tumor-associated antigens might 
be suitable to indicate the response to radiochemother-
apy early. We analyzed the courses of nucleosomes, 
CEA, CA 19-9 and CYFRA 21-1 in 25 colorectal cancer 
 patients during radiochemotherapy (4 postoperative, 
13 preoperative, 8 local relapse therapy). Blood was tak-
en before therapy, daily during the fi rst week, once week-
ly during the following weeks, and at the end of the ra-
diochemotherapy. After a temporary decline 6 h after the 
fi rst irradiation, nucleosomes rose in most patients rap-
idly reaching a maximum during the fi rst days which was 
followed by a subsequent decrease. In patients receiving 
postoperative therapy after complete resection of tumor, 
nucleosome levels generally were lower than in patients 
with preoperative or relapse therapy. Correspondingly, 
CEA, CA 19-9 and CYFRA 21-1 levels of postoperatively 
treated patients were the lowest whereas those with tu-
mor relapse had the highest ones. During preoperative 
therapy, lower nucleosome concentrations were found 
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are phagocytized by neighboring cells and macrophages. 
In case of enhanced cell death, such as during radio- and 
chemotherapy, nucleosomes are also released into circu-
lation  [6, 7] , and are detected in elevated concentrations 
in serum and plasma.  
 Circulating nucleosomes can be quantifi ed directly by 
ELISA techniques  [8] . Previous investigations showed 
low levels of nucleosomes in the serum of healthy indi-
viduals  [9] . In patients with various malignant tumors 
high amounts of nucleosomes appear spontaneously and 
under chemo- and radiotherapy  [10, 11] . Elevated nu-
cleosome levels are also observed in benign pathological 
conditions like infections  [12] , autoimmune diseases  [13, 
14] , graft-versus-host reactions  [15] , trauma  [16] , stroke 
 [17, 18] , and exhaustive exercise  [19] .  
 As the course of nucleosomes correlated with the re-
sponse to radiotherapy and chemotherapy in patients 
with various cancers, they showed potential for the mon-
itoring of systemic therapies  [12, 20] . Additionally recent 
results have revealed that the initial course of nucleo-
somes during radiochemotherapy was a signifi cant indi-
cator for the time to progression in patients with pancre-
atic cancer  [21] . Further in patients with advanced lung 
cancer, nucleosomes were able to predict the response to 
chemotherapy already after the fi rst application indepen-
dently from clinical factors and CYFRA 21-1  [22] . 
 As in the present study on patients with colorectal can-
cer radiochemotherapy was applied in some patients after 
surgical resection of the primary tumor, in others preop-
eratively to reduce tumor volume before resection, and 
in others who suffered from local tumor relapse, we fi rst 
investigated whether the quantity of the marker release 
was associated with the presence of tumor burden during 
therapy. Further, we asked whether the courses of nucleo-
somes and of other tumor-associated antigens during the 
initial phase of radiochemotherapy are able to predict the 
therapy response in colorectal cancer patients early. 
 Patients and Methods 
 Patients 
 In total, 25 patients with colorectal cancer were included in this 
study. All patients were treated with a combined radio- and che-
motherapy. Among them were 4 with postoperative therapy after 
complete resection of tumor, 13 with preoperative therapy, and 8 
with local relapse therapy. All patients were investigated prethera-
peutically by coloscopy, biopsy, and computed whole-body tomog-
raphy. Pathological grading was established in 23 patients, with 
19 patients having a moderate and 4 a poor differentiation grade. 
All but 1 patient had adenocarcinoma. Involvement of lymph 
nodes was proven in 1 patient of the postoperative group, while 3 
patients were free of malignant lymph nodes. Seven patients of the 
preoperative and relapse group were classifi ed as nodal negatives, 
13 as nodal positives ( table 1 ). 
 Treatment planning and fi eld positioning were performed indi-
vidually by 3D calculation (HELAX) and CT scans. Radiation was 
delivered in a three- or four-fi eld technique using a linear accelera-
tor with a photon beam of more than 10 MV. The treated volume 
included the macroscopic tumor with a safety margin of 2–3 cm, 
the perirectal and internal iliac lymph nodes. The anus was only 
irradiated in case of malignant infi ltration of the anal canal. A sin-
gle dose of 1.8 Gy was applied on 5 days a week. Postoperatively 
Postoperative
RCT (n = 4)
Preoperative RCT (n = 13) Relapse
RCT (n = 8)
No Prog. (n = 9) Prog. (n = 4)
Age (median, range), years 65 (54–75) 64 (47–76) 64 (47–73)
Gender (female/male) 2/2 3/10 0/8
Stage
UICC I 0 0 0 1
UICC II 3 4 1 1
UICC III 1 4 3 3
UICC IV 0 1 0 2
Pathological differentiation
Well differentiated 0 0 0 0
Moderately differentiated 3 9 1 6
Poorly differentiated 1 0 2 1
Without classifi cation 0 0 1 1
RCT = Radiochemotherapy; No Prog. = no progression; Prog. = progression.
Table 1. Characteristics of the patients 
investigated
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and preoperatively treated patients received 25–30 fractions with-
in 5–6 weeks. Thus, the total dose was 45.0–54.0 Gy (dose rate ac-
cording the International Commission of Radiation Units and 
Measurements, ICRU 50). Patients with local relapse of tumor re-
ceived 17 fractions (reirradiation), which equals a total dose of 
30.7 Gy.  
 5-Fluorouracil (500 mg/m 2  per day) was additionally given as a 
continuous 5-day infusion on weeks 1 and 5 for the postoperative 
treatment protocol. Patients receiving preoperative and relapse 
therapies received daily infusions of 5-fl uorouracil (350 mg/m 2 ). 
 Blood was taken before the start of therapy, 6 h after the fi rst 
radiation, daily during the fi rst week, once weekly during the fol-
lowing weeks and at the end of radiochemotherapy.  
 In patients treated preoperatively, staging was done before the 
start of radiochemotherapy, in most cases by computed whole-body 
tomography. Response to therapy was determined by postsurgery 
pathological staging within 2 months after the end of therapy. In 
our evaluation, all patients having a downstaging of the tumor or 
alternatively ‘stable disease’ were considered as ‘no progression’. 
They were compared with patients suffering from progressive dis-
ease.  
 The study was approved by the local ethics committee. Before 
inclusion in the study, written informed consent was given by all 
patients. 
 Methods 
 Nucleosome concentrations were determined in serum samples. 
Within 1–2 h after venipuncture the blood samples were centri-
fuged at 3,000  g for 15 min. Subsequently, 10 m M EDTA was 
added as stabilizer and the serum samples were stored at –70  °  C. 
Prior to the measurement of nucleosomes, samples were thawed, 
homogenized and diluted 1:  4 with an incubation buffer.  
 For the quantifi cation of nucleosomes concentrations in serum 
the Cell Death Detection ELISA plus  (Roche Diagnostics) was used. 
In this assay, two monoclonal mouse antibodies directed against 
histones and DNA catch the nucleosomes specifi cally. The anti-
histone antibody binds to the microtiter plate, whereas the anti-
DNA antibody, which is labeled with peroxidase, reacts with 2,2-
azino-di(3-ethylbenzthiazolin-sulfonate). The amount of nucleo-
somes captured by the antibodies is proportional to the resulting 
color development and enables the photometrical quantifi ca-
tion. 
 The tumor-associated antigens CEA, CA 19-9 and CYFRA 21-1 
were determined in all samples by Elecsys 2010, Roche Diagnos-
tics, Germany. 
 Statistics 
 For our evaluation we considered the pretherapeutic concentra-
tions, the levels of day 1 (6 h after the fi rst application of the ther-
apy), day 2 and day 3 of all parameters. The values during the ini-
tial phase of therapy were summarized by the area under the curve 
of days 1–3 (AUC) which includes the concentrations before (day 
1, 0 h), 6 h (day 1, 6 h), 24 h (day 2), and 48 h (day 3) after the start 
of therapy, divided by the number of days. Generally, results are 
presented as medians and ranges. 
 An overall analysis of variance was performed to test the gen-
eral dependency of logarithmical concentrations of nucleosomes, 
CEA, CA 19-9 and CYFRA 21-1 on the treatment group (postop-
erative, preoperative and relapse therapy) and on time [before (day 
1, 0 h) and after (day 1, 6 h to day 3) start of radiochemotherapy]. 
This was done using the SAS procedure MIXED, which can take 
into account dependencies of repeated values of the same patient. 
In addition, adjusted p values were calculated according to the 
number of comparisons between the three treatment groups.  
 In the same way marker concentrations in patients with preop-
erative radiochemotherapy having ‘no progression’ and ‘progres-
sion’ of disease were compared. Additionally the Wilcoxon test was 
used to compare the AUC between both groups. The comparison 
of patients with progression and without progression is shown as 
dot plots. 
 A p value  ! 0.05 was considered statistically signifi cant. All cal-
culations were performed by software of SAS (version 8.2, SAS 
Institute, Cary, N.C., USA). 
 Results 
 Generally, most of the patients showed a temporary 
decrease of the nucleosome concentration 6 h after the 
fi rst irradiation followed by a considerable and rapid in-
crease with a maximum during the following days. Sub-
sequently, the levels declined again. All patients receiving 
postoperative radiochemotherapy after complete resec-
tion of the primary tumor released only low levels of nu-
cleosomes before and during the time of radiochemother-
apy. The initial peak mostly was only little pronounced 
( fi g. 1 a). Patients receiving preoperative therapy showed 
considerably higher nucleosome levels and higher initial 
peaks during radiochemotherapy compared to postopera-
tively treated patients. Within the preoperative group, 
those with response to therapy had lower nucleosome 
concentrations than those with progressive disease 
( fi g. 1 b, c). 
 Between patients receiving postoperative therapy and 
those with preoperative and relapse therapy, signifi cant 
differences were observed concerning nucleosomes and 
other tumor-associated antigens. When the primary tu-
mor was removed before radiochemotherapy, the mark-
er concentrations were notably lower than in the pres-
ence of tumor burden, particularly for nucleosomes and 
also for CEA and CYFRA 21-1. Additionally, the levels 
of the tumor-associated antigens CEA, CA 19-9 and 
 CYFRA 21-1 were further enhanced in patients who suf-
fered from tumor relapse compared to those with a pri-
mary tumor. The detailed results are summarized in 
 table 2 . 
 In patients with primary advanced colorectal cancer, 
preoperative radiochemotherapy was applied to reduce 
the tumor volume. Concerning the change of tumor stage 
according to the UICC classifi cation at the time of the 
preoperative restaging investigation, 4 patients showed 
remission, 5 patients had stable disease and 4 patients 
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suffered from progression. When combining patients 
with remission and stable disease in the group of ‘no pro-
gression’, they had a signifi cantly (p = 0.028) smaller AUC 
compared to those with progressive disease ( fi g. 2 ). The 
biological markers CEA, CA 19-9 and CYFRA 21-1 could 
not discriminate between the nonprogressive and the pro-
gressive group ( table 3 ). 
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 Fig. 1. Characteristic courses of nucleo-
somes in serum of a patient with rectal can-
cer (pT3, pN0, M0, G3) during radioche-
motherapy after complete resection of tu-
mor ( a ), a patient with rectal cancer (T3, 
N0, M0, G2) during preoperative radioche-
motherapy without progression of disease 
( b ), and a patient with rectal cancer (T3, 
N1, M0, G3) during preoperative radioche-
motherapy with progressive disease ( c ).  
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 Discussion 
 Multimodal therapy strategies have shown to increase 
the treatment effi cacy in many cancer types, such as 
colorectal cancer. In the preoperative as well as in the 
postoperative setting, radio- and chemotherapy often are 
combined because they attack cancer cells at different 
levels. As the combined application of both modalities is 
associated with enhanced toxicity, predictive and prog-
nostic markers are required to indicate early whether the 
treatment applied will be successful or whether it should 
be changed. 
 As apoptosis is one of the main mechanisms leading 
to the demise of cancer cells, blood markers refl ecting the 
apoptotic process and also tumor-associated antigens 
might be well suited for this purpose. Typical cell death 
products are circulating nucleosomal DNA fragments 
which are created after endonucleatic cleavage of the 
chromatin and subsequent release by dying cells. Recent 
work has shown that the course of nucleosomes corre-
lated with the response to radiotherapy and chemothera-
py in patients with various cancers  [12, 20] . Additionally, 
the initial course of nucleosomes during radiochemother-
apy was a signifi cant indicator for the time to progression 
Table 2. Medians and ranges of nucleosomes, CEA, CA 19-9 and CYFRA 21-1 in patients receiving postoperative, preoperative and 
relapse radiochemotherapy concerning the pretherapeutic value (day 1, 0 h), the values 6 h after the start of therapy (day 1, 6 h) and dur-
ing the following days (day 2; day 3)
Nucleosomes
ng/ml
CEA
ng/ml
CYFRA 21-1
ng/ml
CA 19-9
U/ml
Postoperative RCT (n = 4)
Day 1, 0 h 192 (86–530) 2.0 (0.8–3.6) 0.9 (0.5–1.4) 11.1 (4.3–13.0)
Day 1, 6 h 126 (78–424) 1.1 (0.7–3.7) 1.3 (0.6–1.5) 8.6 (4.1–10.4)
Day 2 208 (45–274) 1.7 (0.8–3.2) 1.1 (0.6–1.1) 9.5 (4.4–11.9)
Day 3 238 (135–464) 1.9 (1.2–3.0) 1.1 (0.6–1.2) 8.9 (8.9–9.9)
Preoperative RCT (n = 13)
Day 1, 0 h 1,154 (238–4,422) 4.6 (1.5–43.3) 1.7 (0.6–39.4) 11.8 (4.0–65.4)
Day 1, 6 h 502 (145–957) 7.3 (1.4–45.2) 1.5 (0.9–4.9) 11.3 (3.7–59.7)
Day 2 732 (370–1,329) 5.0 (1.5–45.5) 2.0 (0.9–36.9) 11.0 (3.9–47.1)
Day 3 879 (174–2,365) 2.7 (1.5–41.7) 1.9 (1.0–4.8) 10.8 (3.7–52.6)
Relapse RCT (n = 8)
Day 1, 0 h 993 (443–3,767) 17.3 (1.3–117) 2.2 (0.6–9.8) 68.8 (0.6–532)
Day 1, 6 h 952 (321–1,158) 18.9 (4.0–101) 2.6 (0.8–8.6) 105 (0.6–494)
Day 2 536 (165–2,535) 20.0 (4.2–94.1) 2.7 (1.1–8.6) 98.9 (0.6–461)
Day 3 440 (241–3,955) 17.7 (1.2–99.2) 3.0 (0.9–7.8) 107 (6.7–509)
Analysis of variance Nucleosomes CEA CYFRA 21-1 CA 19-9
p value p adj. p value p adj. p value p adj. p value p adj.
Postoperative vs. preoperative
Effect of therapy group <0.001 <0.001 NS NS NS
Effect of days of therapy NS NS NS NS
Effect of interaction NS NS NS NS
Postoperative vs. relapse
Effect of therapy group 0.001 0.003 0.012 0.036 0.031 0.093 NS
Effect of days of therapy NS 0.008 0.024 NS 0.002 0.006
Effect of interaction NS NS NS NS
Preoperative vs. relapse
Effect of therapy group NS NS NS NS
Effect of days of therapy 0.011 0.033 0.001 0.003 NS NS
Effect of interaction NS NS NS NS
RCT = Radiochemotherapy; adj. = adjusted; NS = not signifi cant.
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in patients with pancreatic cancer  [21] . Further in pa-
tients with advanced lung cancer during chemotherapy, 
nucleosomes were able to predict the response to therapy 
early already after the fi rst application  [22] . 
 Here we investigated the course of nucleosomes and 
of other tumor-associated antigens in colorectal cancer 
patients during the initial phase of radiochemotherapy 
asking whether they are able to predict the response to 
therapy early. As radiochemotherapy was applied in some 
patients preoperatively to reduce tumor volume before 
resection, in others who suffer from local tumor relapse, 
and fi nally in others still after surgical resection of the 
primary tumor, it was further analyzed whether the quan-
tity of the marker release was associated with the presence 
of tumor burden during therapy. 
 Corresponding with earlier fi ndings in pancreatic can-
cer patients  [21] , we also observed in most of the patients 
with colorectal cancer a temporary decrease of the nucleo-
some concentration 6 h after the fi rst irradiation followed 
by a rapid increase and a subsequent decline. It is known 
that already the fi rst irradiation damages DNA effective-
ly by single and double DNA strand breaks, and further 
by changes of the ionic setting, production of free radicals 
and other reactive products  [23] . As described by Shi-
Table 3. Medians of nucleosomes, CEA, CA 19-9 and CYFRA 21-1 in preoperatively treated patients without (No Prog.) and with pro-
gression (Prog.) of disease
Nucleosomes CEA CYFRA 21-1 CA 19-9
No Prog. Prog. No Prog. Prog. No Prog. Prog. No Prog. Prog.
Day 1, 0 h 942 2,084 3.0 9.1 1.4 2.4 11.7 32.0
Day 1, 6 h 126 512 1.9 8.7 1.3 2.7 11.3 30.9
Day 2 208 1,103 2.3 8.3 1.9 2.5 10.6 13.6
Day 3 238 1,775 2.0 10.1 1.7 2.8 7.7 13.9
Analysis of variance: No Prog. vs. Prog.
Effect of therapy group p = 0.052 NS NS NS
Effect of days of therapy p = 0.005 NS NS NS
Effect of interaction NS NS NS NS
NS = Not signifi cant.
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 Fig. 2. Distribution of nucleosomes during 
the fi rst 3 days of treatment in preopera-
tively treated colorectal cancer patients 
without progression ( y ) and with progres-
sion ( I ) of disease. The discriminating 
power between both groups concerning the 
prediction of therapy response is p = 0.052 
(analysis of variance) for single nucleosome 
values and p = 0.028 (Wilcoxon text) for 
AUC. 
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nomiya  [24] , high irradiation doses predominately cause 
irreparable DNA damage and induce early, premitotic 
apoptosis, whereas low doses cause less severe DNA dam-
age which, in consequence, does not lead to acute cell 
death. Instead, cells are arrested in their cell cycles to en-
able the repair of the damaged DNA. In case of insuffi -
cient or impaired repair mechanisms, cells will undergo 
delayed, postmitotic apoptosis  [25, 26] . This might ex-
plain the temporary decrease immediately after therapeu-
tic irradiation with 1.8 Gy per fraction and the delayed 
maximum after 1–3 days of the appearance of apoptotic 
products in circulation, which is in line with earlier  in 
vitro  fi ndings, too  [27] . 
 The nucleosome values in postoperatively treated pa-
tients were signifi cantly lower compared with patients 
still having tumor masses and receiving preoperative or 
relapse therapy. During postoperative radiochemothera-
py, nucleosome levels increased only slightly after the 
start of treatment and remained at low levels during the 
whole follow-up time. On the one hand, this observation 
was surprising as we expected a considerable number of 
‘normal cells’ being damaged by the therapy applied. On 
the other hand, it was in concordance with recent in vitro 
 fi ndings which showed a signifi cantly higher release of 
nucleosomal DNA fragments after irradiation of lung 
cancer cells than of ‘normal’ bronchoepithelial cells, par-
ticularly at low doses  [28] . 
 Concerning the tumor-associated antigens CEA and 
CYFRA 21-1, of which the latter has also been described 
as an apoptotic marker  [29] , the levels during postopera-
tive therapy were notably lower than in the presence of 
tumor burden, too. Additionally, the concentrations of 
CEA, CA 19-9 and CYFRA 21-1 were further enhanced 
in patients with tumor relapse compared to those with 
primary tumors. As in recurrent disease cancer cells often 
have spread beyond the organ frontiers via venous, arte-
rial or lymphatic ways, the higher levels of cancer antigens 
shed from these cells are well comprehensible. Unlike in 
our present results, nucleosome levels in postoperative 
and primary-treated pancreatic cancer patients were ear-
lier found to be comparable. However, this was due to an 
incomplete resection with remaining tumor burden in all 
pancreatic cancer patients undergoing surgery  [21] . 
 The potential for the early prediction of therapy re-
sponse by apoptotic markers and tumor-associated anti-
gens was investigated in patients who were treated pre-
operatively to reduce tumor volume before resection. 
During this time 9 patients had at least stable disease 
whereas 4 suffered from progressive disease. The concen-
trations of nucleosomes were lower in patients with ‘no 
progression’ than in those with progression. Even if for 
single days, the difference was only borderline signifi cant 
(p = 0.052), it became more evident when these values 
were integrated in the AUC (p = 0.028). Our observations 
are consistent with earlier fi ndings in pancreatic cancer 
patients when a small AUC predicted a longer progres-
sion-free interval  [21] . A tendency of higher values in the 
nonresponsive group was also valid for the tumor-associ-
ated antigens CEA, CA 19-9 and CYFRA 21-1; however, 
they could not discriminate between the nonprogressive 
and progressive group. As CEA and CA 19-9 have a con-
siderably longer half-life in circulation (2–8 days), fast 
changes of their concentrations in serum were not ex-
pected. In contrast, nucleosomal DNA fragments, which 
after the occurrence of cell death are more quickly re-
leased into and eliminated from circulation  [13, 30] , are 
supposed to refl ect more accurately the quantity of dying 
cells at a certain time point. Thus, patients with smaller 
or less aggressive tumors, which are linked with lower cell 
death rates, less pronounced release of nucleosomal DNA 
into circulation, and/or more effective systems to elimi-
nate apoptotic products from circulation, seem to be as-
sociated with a better outcome after radiochemother-
apy. 
 In conclusion, the course of nucleosomes during the 
initial phase of radiochemotherapy, refl ected by the AUC, 
has turned out to be a valuable marker for the early esti-
mation of the response to therapy already in this limited 
set of colorectal cancer patients. Further prospective 
studies are warranted to validate these fi ndings. 
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